These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24919804)

  • 121. A novel BLK-induced tumor model.
    Petersen DL; Berthelsen J; Willerslev-Olsen A; Fredholm S; Dabelsteen S; Bonefeld CM; Geisler C; Woetmann A
    Tumour Biol; 2017 Jul; 39(7):1010428317714196. PubMed ID: 28670978
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
    Palomero T; Couronné L; Khiabanian H; Kim MY; Ambesi-Impiombato A; Perez-Garcia A; Carpenter Z; Abate F; Allegretta M; Haydu JE; Jiang X; Lossos IS; Nicolas C; Balbin M; Bastard C; Bhagat G; Piris MA; Campo E; Bernard OA; Rabadan R; Ferrando AA
    Nat Genet; 2014 Feb; 46(2):166-70. PubMed ID: 24413734
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.
    Imam MH; Shenoy PJ; Flowers CR; Phillips A; Lechowicz MJ
    Leuk Lymphoma; 2013 Apr; 54(4):752-9. PubMed ID: 23004352
    [TBL] [Abstract][Full Text] [Related]  

  • 126. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
    Zhang H; Peng C; Hu Y; Li H; Sheng Z; Chen Y; Sullivan C; Cerny J; Hutchinson L; Higgins A; Miron P; Zhang X; Brehm MA; Li D; Green MR; Li S
    Nat Genet; 2012 Jul; 44(8):861-71. PubMed ID: 22797726
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia.
    Montero-Ruíz O; Alcántara-Ortigoza MA; Betancourt M; Juárez-Velázquez R; González-Márquez H; Pérez-Vera P
    Leuk Res; 2012 Sep; 36(9):1105-11. PubMed ID: 22748822
    [TBL] [Abstract][Full Text] [Related]  

  • 128. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.
    van Kester MS; Borg MK; Zoutman WH; Out-Luiting JJ; Jansen PM; Dreef EJ; Vermeer MH; van Doorn R; Willemze R; Tensen CP
    J Invest Dermatol; 2012 Aug; 132(8):2050-9. PubMed ID: 22513784
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 130. COX-2 is a novel target in therapy of mycosis fungoides.
    Kopp KL; Dabelsteen S; Krejsgaard T; Eriksen KW; Geisler C; Becker JC; Wasik M; Ødum N; Woetmann A
    Leukemia; 2010 Dec; 24(12):2127-9. PubMed ID: 20882047
    [No Abstract]   [Full Text] [Related]  

  • 131. A novel xenograft model of cutaneous T-cell lymphoma.
    Krejsgaard T; Kopp K; Ralfkiaer E; Willumsgaard AE; Eriksen KW; Labuda T; Rasmussen S; Mathiesen AM; Geisler C; Lauenborg B; Becker JC; Zhang Q; Wasik MA; Odum N; Woetmann A
    Exp Dermatol; 2010 Dec; 19(12):1096-102. PubMed ID: 20629733
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 133. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
    Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
    Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.
    Krejsgaard T; Vetter-Kauczok CS; Woetmann A; Kneitz H; Eriksen KW; Lovato P; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N
    Blood; 2009 Jun; 113(23):5896-904. PubMed ID: 19351960
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase.
    Malek SN; Dordai DI; Reim J; Dintzis H; Desiderio S
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7351-6. PubMed ID: 9636152
    [TBL] [Abstract][Full Text] [Related]  

  • 136. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).
    Petersen DL; Krejsgaard T; Berthelsen J; Fredholm S; Willerslev-Olsen A; Sibbesen NA; Bonefeld CM; Andersen MH; Francavilla C; Olsen JV; Hu T; Zhang M; Wasik MA; Geisler C; Woetmann A; Odum N
    Leukemia; 2014 Oct; 28(10):2109-12. PubMed ID: 24919804
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.